Lilly’s flush pipeline makes it Wall Street darling
If you follow the daily drumbeat of news emanating out of Lilly Corporate Center, you might not grasp how phenomenally well the company is poised to perform in the coming years.
Pharmaceutical
Articles
Hope at Lilly after years of Alzheimer’s failures
Lilly has spent three decades and more than $3 billion trying to find a way to treat Alzheimer’s disease. Its latest drug, donanemab, finally shows real promise.
J&J asks U.S. regulators to OK its one-shot COVID-19 vaccine
J&J’s vaccine was safe and offered strong protection against moderate to severe COVID-19, according to preliminary results from a massive international study.
Indiana to receive $12.6M as part of $573M opioid crisis settlement
The global business consulting firm McKinsey & Company has agreed to a $573 million settlement with 49 states over its role in advising companies on how to “supercharge” opioid sales amid an overdose crisis.
In midst of pandemic, drugmakers raise prices on hundreds of prescription drugs
So far this month, drugmakers have hiked prices on 636 drugs, according to research by GoodRx, which tracks prescription drug prices and offer a mobile app to help consumers find the lowest prices on hundreds of drugs.
Lilly shares surge after its potential Alzheimer’s drug slows cognitive decline
The experimental drug, donanemab, could be a huge breakthrough for Lilly, which has spent billions of dollars over 30 years researching treatments for Alzheimer’s disease, only to see them fall short in clinical trials.
Lilly’s COVID treatment sparks little demand
For a highly touted drug meant to keep throngs of people out of hospitals during a pandemic, Eli Lilly and Co.’s wonder treatment bamlanivimab sure has been slow to catch on.
INCog BioPharma Services selects site, expands plans for Fishers manufacturing facility
INCog BioPharma Services has purchased 16 acres of undeveloped land in Fishers for its planned new biopharmaceutical manufacturing facility. The $60 million project has grown in size.
China OKs first homegrown vaccine as COVID-19 surges globally
The Sinopharm vaccine, like the AstraZeneca one, could be easier for countries around the world to handle since they can be stored at normal fridge temperatures.
Novavax’s COVID-19 vaccine to be studied in United States
The candidate made by Novavax Inc. is the fifth to reach final-stage testing in the U.S. Some 30,000 volunteers are needed to prove if the vaccine–a different kind than its Pfizer and Moderna competitors–really works and is safe.
Pfizer, BioNTech to supply U.S. with additional 100M vaccines doses
Under the nearly $2 billion deal announced Wednesday, the companies will deliver at least 70 million additional doses by June 30, with the remaining 30 million to be delivered no later than July 31.
Justice Department sues Walmart, says it helped fuel opioid crisis
The lawsuit, filed Tuesday by the Justice Department, says the nation’s largest retailer did not properly screen prescriptions at its 5,000 pharmacies. The agency is seeking civil penalties that could total billions of dollars.
Demand surprisingly low for COVID-19 antibody drugs, but shortages still loom
Red tape, staff shortages, testing delays and strong skepticism are keeping many patients and doctors from the drugs made by Eli Lilly and Co. and Regeneron Pharmaceuticals.
U.S. awaits word on 2nd vaccine as COVID-19 outbreak worsens
The Food and Drug Administration was evaluating a shot developed by Moderna Inc. and the National Institutes of Health and was expected to give it the green light soon, clearing the way for its use to begin as early as Monday.
FDA plans to OK second COVID-19 vaccine after panel endorsement
Once FDA’s emergency use authorization is granted, Moderna will begin shipping millions of doses, earmarked for health workers and nursing home residents, to boost the largest vaccination effort in U.S. history.
FDA says Pfizer vaccine contains extra doses, expanding nation’s supply
The Food and Drug Administration said Wednesday that pharmacists can draw additional doses from vials of the Pfizer coronavirus vaccine, potentially expanding the country’s supply by millions of doses.
FDA review clears path for second coronavirus vaccine, this one developed by Moderna
The vaccine appears poised for regulatory clearance after a detailed data review by Food and Drug Administration scientists confirmed the two-shot regimen was “highly effective” in a clinical trial and carried no serious safety concerns.
Eli Lilly shares rise on Prevail acquisition, optimistic forecast
Lilly stock climbed Tuesday after the drugmaker laid out a better-than-expected revenue forecast and plans to buy a young company developing a potential Parkinson’s disease treatment.
Lilly acquiring gene therapy startup for up to $1 billion
Eli Lilly and Co. on Tuesday announced that it is buying New York-based Prevail Therapeutics Inc., an emerging player in the sizzling-hot area of gene therapies, which targets Parkinson’s disease and other brain-related maladies.
Vaccines roll out as officials share months-long timeline for immunization effort
Federal officials hope to have given both of the required vaccine doses to 100 million people by the end of March. It could take two to three more months to immunize enough people to prompt herd immunity.